HomeCompareMIXT vs PFE

MIXT vs PFE: Dividend Comparison 2026

MIXT yields 1.65% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MIXT wins by $28.67M in total portfolio value
10 years
MIXT
MIXT
● Live price
1.65%
Share price
$14.55
Annual div
$0.24
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.72M
Annual income
$25,722,713.87
Full MIXT calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MIXT vs PFE

📍 MIXT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMIXTPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MIXT + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MIXT pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MIXT
Annual income on $10K today (after 15% tax)
$140.21/yr
After 10yr DRIP, annual income (after tax)
$21,864,306.79/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, MIXT beats the other by $21,841,986.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MIXT + PFE for your $10,000?

MIXT: 50%PFE: 50%
100% PFE50/50100% MIXT
Portfolio after 10yr
$14.38M
Annual income
$12,874,486.29/yr
Blended yield
89.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MIXT
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Price Target
$12.00
-17.5% upside vs current
Range: $12.00 — $12.00
Altman Z
4.4
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MIXT buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMIXTPFE
Forward yield1.65%6.13%
Annual dividend / share$0.24$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$28.72M$49.6K
Annual income after 10y$25,722,713.87$26,258.71
Total dividends collected$28.46M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$12.00$27.50

Year-by-year: MIXT vs PFE ($10,000, DRIP)

YearMIXT PortfolioMIXT Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,030$329.90$9,153$693.39+$1.9KMIXT
2$12,482$680.14$8,593$849.25+$3.9KMIXT
3$14,795$1,438.66$8,336$1,066.78+$6.5KMIXT
4$19,017$3,187.27$8,437$1,384.80+$10.6KMIXT
5$28,007$7,657.99$9,013$1,875.40+$19.0KMIXT
6$51,047$21,079.98$10,306$2,680.72+$40.7KMIXT
7$126,437$71,816.86$12,820$4,101.38+$113.6KMIXT
8$467,776$332,488.59$17,673$6,826.70+$450.1KMIXT
9$2,799,771$2,299,250.67$27,543$12,591.86+$2.77MMIXT
10$28,718,469$25,722,713.87$49,560$26,258.71+$28.67MMIXT

MIXT vs PFE: Complete Analysis 2026

MIXTStock

MiX Telematics Limited provides fleet and mobile asset management solutions through software-as-a-service (Saas) delivery model. The company offers MiX Fleet Manager, a web-based application, which provides commercial fleet management solution that gives user live and historical views of driver and vehicle performance information, including vehicle tracking and status information, as well as alerts and notifications; MiX Asset Manager, a portfolio of asset tracking products comprising generators, light towers, storage tanks, and pumps; and Matrix, a mobile asset management solutions that offers real-time and historical vehicle tracking and positioning, unauthorized vehicle use alerts, panic emergency response, crash alerts, driver behavior alerts, fuel tax logbooks, and vehicle maintenance notifications for entry-level fleets and consumers. It also provides Beam-e, a crowdsourcing platform to locate vehicles without the expense of utilizing a traditional cellular network connection, and entry-level tracking and recovery services; MiX Now, a system that helps companies monitor and manage the behavior and performance of their vehicles and drivers. It delivers fleet and mobile asset management solutions as SaaS to 815,165 subscribers in South Africa, the Americas, the Middle East, Australia, Europe, and Brazil. MiX Telematics Limited was founded in 1996 and is headquartered in Boca Raton, Florida.

Full MIXT Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MIXT vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MIXT vs SCHDMIXT vs JEPIMIXT vs OMIXT vs KOMIXT vs MAINMIXT vs JNJMIXT vs MRKMIXT vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.